Clinical Trial Update: Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated a combination of bortezomib, lenalidomide, and dexamethasone in multiple myeloma patients undergoing stem cell transplant. The study w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Refractory Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2015-03-09